Literature DB >> 2996040

Amitriptylinoxide: receptor-binding profile compared with other antidepressant drugs.

H O Borbe, O Zierenberg.   

Abstract

The interactions of amitriptylinoxide and various antidepressant drugs with different neurotransmitter and drug receptors were investigated by receptor binding studies. Amitriptylinoxide had less affinity than amitriptyline for most of the receptors studied. Half maximal inhibition of acetylcholine receptor binding occurred for amitriptylinoxide at 18 mumol/l (amitriptyline: 0.32 mumol/l). Comparing all studied antidepressants for muscarinic acetylcholine receptor binding, amitriptylinoxide had the weakest affinity of all tested tricyclic compounds. Also the affinity of amitriptylinoxide for alpha-receptor binding was about 60 fold less than that of amitriptyline. For all antidepressants investigated, the lowest affinities were found for benzodiazepine, opiate and beta-receptor binding. The weak affinities of amitriptylinoxide for various receptors may be responsible for its reduced side-effects, while it still retains potent antidepressant properties by stabilising the amitriptyline-level in the brain.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996040     DOI: 10.1055/s-2007-1017388

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  3 in total

1.  Does Ca2+ channel blockade modulate the antidepressant-induced changes in mechanisms of adrenergic transduction?

Authors:  I Nalepa; M Kowalska; G Kreiner; J Vetulani
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Mode of antinociceptive action of flupirtine in the rat.

Authors:  I Szelenyi; B Nickel; H O Borbe; K Brune
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

3.  The effect of chronic administration of amitriptyline on the effects of subsequent electroconvulsive treatment on responsiveness of alpha 1-and beta-adrenoceptors in the rat cortical slices.

Authors:  J Vetulani; I Nalepa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.